GlassScriptPhysician profile
Mary Burgeson
NPI 1972565026
$8,522.70
in general payments reported to CMS, 2019-2025
43 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $500 · 2021: $1,221 · 2022: $1,462 · 2023: $1,193 · 2024: $1,476 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,375 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.60 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,032.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $867.24 | 2020-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $748.44 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $591.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $551.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $474.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $431.70 | 2019-2025 | Repatha, Evenity, Otezla |
| Mylan Specialty L.P. | $319.10 | 2019-2024 | Yupelri |
| Astellas Pharma US INC | $304.38 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $280.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.90 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $261.69 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.88 | 2020-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.65 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $205.63 | 2020-2025 | Verquvo, Belsomra, Steglatro |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Burgeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.